Skip to main
DMAC
DMAC logo

DMAC Stock Forecast & Price Target

DMAC Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

DiaMedica Therapeutics is seeing a positive outlook driven by the promising interim Phase 2 results for its preeclampsia treatment, DM199, which exhibited statistically significant blood pressure reduction without placental transfer. The company has successfully positioned DM199 for further cohort enrollment, enhancing its credibility as a critical therapeutic option in this area. Additionally, the recombinant KLK1 mechanism's potential benefits for acute ischemic stroke patients, especially those who do not respond to standard thrombolytic therapies, supports a strong foundation for future clinical advancements and market opportunities.

Bears say

The financial outlook for DiaMedica Therapeutics Inc. appears negative due to several challenges associated with its clinical development programs. Firstly, historical studies related to its disease-modifying candidates for preeclampsia have not successfully prolonged gestation, raising concerns about the potential for achieving peak commercial revenue estimates in their overall market. Additionally, the company faces significant risks in securing necessary capital for ongoing operations, compounded by uncertainties surrounding program development and commercialization that may hinder growth and revenue generation.

DMAC has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DiaMedica Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DiaMedica Therapeutics Inc (DMAC) Forecast

Analysts have given DMAC a Strong Buy based on their latest research and market trends.

According to 4 analysts, DMAC has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DiaMedica Therapeutics Inc (DMAC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.